WORLDWIDE SALES OF NAPROSYN, ANAPROX APPROACH $600 MIL. IN FY 1987; NSAID SALES UP 15% IN U.S. TO OVER $410 MIL.; SYNTEX NET INCOME JUMPS 20%
Worldwide sales of Naprosyn and Anaprox approached $600 mil. in fiscal 1987, Syntex reported for the 12 months ended July 31. Combined sales of the two nonsteroidal anti-inflammatory drugs were up 17% for the 12 months to $594 mil. and helped pace a 15% jump in corporate volume, from $980 mil. to $1.1 bil. Income from continuing operations in FY 1987 rose 20% to $249 mil. While the U.S. remains the dominant market for naproxen and naproxen sodium, the largest percentage increase occurred outside the U.S., where sales were up 22% to $184 mil. Domestic volume of $410 mil. reflected a 15% increase over fiscal 1986 levels. "Naprosyn remained the largest-selling prescription drug for arthritis and the third largest-selling prescription drug of any type in the U.S. in fiscal 1987," Syntex commented. Pharmaceutical sales, heavily dominated by Naprosyn and Anaprox, increased 15% to $926 mil., with about two-thirds, or $613 mil., occurring in the U.S. "Increased sales were primarily due to increased unit volume and selected price increases," the company explained. "The favorable impact of changes in currency exchange rates contributed approximately $24 mil. to sales outside the U.S.; however, this benefit was substantially offset by the negative impact of a weaker U.S. dollar on costs and expenses in certain countries outside the U.S." For the fourth quarter ended July 31, Syntex reported a 12% increase in pharmaceutical sales to $237 mil. Naprosyn and Anaprox sales rose 14% to $149 mil., as domestic sales hit nearly $100 mil. Corporate volume was up 12% for the three months to $289 mil., with the U.S. making up about $185 mil. The company's bottom line soared 90% to $55 mil., reflecting a fourth quarter 1986 loss on the discontinuation of the ophthalmics and dental businesses. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth